Equity Overview
Price & Market Data
Price: $1.90
Daily Change: +$0.015 / 0.79%
Range: $1.84 - $1.95
Market Cap: $52,656,364
Volume: 244,842
Performance Metrics
1 Week: 5.28%
1 Month: -9.33%
3 Months: -13.86%
6 Months: -29.55%
1 Year: -44.10%
YTD: -12.27%
Company Details
Employees: 25
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of Parkinson's disease, currently in a Phase 1b study in people with Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is based in Bethesda, Maryland.